Key Highlights

  • QuidelOrtho shares plummeted after management slashed full-year 2026 guidance.
  • Revenue guidance was cut to $2.52-$2.60 billion.
  • Adjusted EPS guidance was cut to $0.65-$0.90.
  • The downward revision stems from IVD pricing headwinds in China and waning international respiratory Demand .

QuidelOrtho ( Nasdaq : QDEL) shares plummeted as management slashed full-year 2026 revenue guidance to $2.52 billion to $2.60 billion and adjusted EPS guidance to $0.65 to $0.90, down significantly from previous ranges.

What Happened

The downward revision stems from IVD pricing headwinds in China and waning international respiratory demand, overshadowing a second-quarter revenue beat.

Respiratory diagnostic testing volumes tend to be seasonal and closely tied to infection rates, meaning a decline in international demand for these products can meaningfully affect a diagnostics company's revenue base outside of any pricing-related pressure.

Market Reaction

Shares fell sharply as investors focused on the scale of the guidance cuts, which overshadowed the positive second-quarter revenue beat reported in the same release.

The combination of pricing pressure in one major market and softening demand in another suggests the headwinds facing QuidelOrtho are broad-based rather than isolated to a single product line or geography.

Outlook

Continued monitoring of IVD pricing trends in China and international respiratory demand is likely to remain the key Factor shaping sentiment toward QuidelOrtho's stock going forward.

Investors are likely to watch for any signs of stabilization in Chinese pricing dynamics or a rebound in respiratory testing volumes as potential catalysts that could support a recovery from the current guidance range.